RxDoctor Payments Data

Sonya Milheim

Psychiatric/Mental Health · Kalispell, MTNPI 1225154453

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 50.8% of the total. Reporting peaked in 2021 at $218 and has fallen 68.7% since, to $68 in 2025.

$538in general payments, 2019–2025

Across 31 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$273
  • Otsuka America Pharmaceutical, Inc.$72
  • Alkermes, Inc.$37
  • Axsome Therapeutics, Inc.$32
  • AbbVie$31
  • Johnson & Johnson$28
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$538100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$538 in reported general payments places this provider in the 80th percentile of 142 psychiatric/mental health providers in Montana.

See all psychiatric/mental health providers in Montana

Medicare billing

Part B allowed, 2024
$23,155
Medicare patients
39
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$143,492
VraylarCariprazine Hcl29$39,189
TrintellixVortioxetine Hydrobromide21$9,195
Clozapine26$2,943
Lurasidone Hcl22$2,120
Ziprasidone Hcl36$1,763
Aripiprazole72$1,174
Desvenlafaxine Succinate ErDesvenlafaxine Succinate25$1,014
Olanzapine58$838
Buspirone Hcl60$810
Fluoxetine Hcl77$778
Gabapentin39$671
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine41$650
Bupropion XlBupropion Hcl57$616
Mirtazapine18$590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$31$39,18929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 142 psychiatric/mental health providers in Montana.

Other psychiatric/mental health in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →